Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 5/20 | 0.79 |
| ▸ | MAPT | P10636 | 1/20 | 0.73 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.67 |
| ▸ | ITGAM | P11215 | 2/20 | 0.67 |
| ▸ | APEX1 | P27695 | 1/20 | 0.62 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13056334 | 1.00 | MAP3K5 (0.79) | MAP3K5MAPTITGB2ITGAMAPEX1 | |
| SCHEMBL3894018 | 1.00 | MAP3K5 (0.79) | MAP3K5MAPTITGB2ITGAMAPEX1 | |
| SCHEMBL8290217 | 0.90 | MAP3K5 (0.76) | MAP3K5MAPTITGB2ITGAMAPEX1 | |
| SCHEMBL3893925 | 0.90 | MAP3K5 (0.79) | MAP3K5MAPTITGB2ITGAMHIF1AN | |
| SCHEMBL3893918 | 0.90 | MAP3K5 (0.79) | MAP3K5MAPTITGB2ITGAMHIF1AN | |
| SCHEMBL13081591 | 0.90 | MAP3K5 (0.75) | MAP3K5MAPTAPEX1 | |
| SCHEMBL3905865 | 0.88 | MAP3K5 (1.00) | MAP3K5MAPTAPEX1 | |
| SCHEMBL3905863 | 0.88 | MAP3K5 (1.00) | MAP3K5MAPTAPEX1 | |
| SCHEMBL13056333 | 0.88 | MAP3K5 (0.72) | MAP3K5MAPTAPEX1 | |
| SCHEMBL16154646 | 0.87 | ITGB2 (0.62) | MAP3K5MAPTITGB2ITGAMHIF1AN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137644-A1 | RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-05-28 | — | — | US | claimed |
| WO-2005041951-A2 | RHODANINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | RIGEL PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | WO | claimed |
| US-9206412-B2 | Thioxothiazolidine inhibitors | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2015-12-08 | — | — | US | disclosed |
| US-9206412-B2 | Thioxothiazolidine inhibitors | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2015-12-08 | — | — | US | disclosed |
| US-7566732-B2 | Rhodanine compositions for use as antiviral agents | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566732-B2 | Rhodanine compositions for use as antiviral agents | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566732-B2 | Rhodanine compositions for use as antiviral agents | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-28 | — | — | US | disclosed |
| US-20090137644-A1 | RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20090137644-A1 | RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20090137644-A1 | RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20060276520-A1 | Rhodanine derivatives and pharmaceutical compositions containing them | RIGEL PHARMACEUTICALS, INC. (US) | 2006-12-07 | — | — | US | disclosed |
| WO-2005041951-A2 | RHODANINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | RIGEL PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| WO-2004043955-A1 | RHODANINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | RIGEL PHARMACEUTICALS, INC. (US) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276520-A1 | Rhodanine derivatives and pharmaceutical compositions containing them | UBQLN1, UBQLN2, UBE2G2 | MAP3K5 1092/4885MAPT 1187/4885ITGB2 4830/4885 |
| US-20090137644-A1 | RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS | RBX1, ITCH, UBQLN1 | MAP3K5 1460/4885MAPT 880/4885ITGB2 4875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.